Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein… - The Lancet …, 2020 - thelancet.com
Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …
被引用次数：440 相关文章

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu… - The lancet …, 2020 - mdanderson.elsevierpure.com
Background: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata… - The Lancet …, 2020 - pure.johnshopkins.edu
Background: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata… - The Lancet …, 2020 - mayoclinic.elsevierpure.com
Background: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata… - The Lancet …, 2020 - jhu.pure.elsevier.com
Background: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

[引用][C] Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein… - The Lancet …, 2020 - cir.nii.ac.jp
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140):
an open-label, multicentre, phase 1b study | CiNii Research CiNii 国立情報学研究所 学術情報 …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.

MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein… - The Lancet …, 2020 - europepmc.org
BACKGROUND: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity
through multiple mechanisms and augmented antitumour activity in multiple malignancies …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata… - The Lancet …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata… - The Lancet …, 2020 - snucm.elsevierpure.com
Background: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MS Lee, BY Ryoo, CH Hsu, K Numata… - The Lancet …, 2020 - researchwithrutgers.com
Background: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through
multiple mechanisms and augmented antitumour activity in multiple malignancies. We …